Literature DB >> 17349859

Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons.

David A Lewis1, Takanori Hashimoto.   

Abstract

Schizophrenia is a devastating illness that is manifest through a variety of clinical signs and symptoms. Among these, impairments in certain critical cognitive functions, such as working memory, appear to represent the core features of the disorder. In this chapter, we review the evidence indicating that disturbances in neurotransmission by a subset of GABA neurons in the dorsolateral prefrontal cortex are commonly present in schizophrenia. Despite both pre- and postsynaptic compensatory responses, the resulting pathophysiological process, alterations in the perisomatic inhibitory regulation of pyramidal neurons, underlies a reduced capacity for the synchronization of neuronal activity at gamma frequencies that is required for working memory function. We also discuss several pathogenetic mechanisms that could rise to the alterations in GABA neurotransmission and consider the implication of these findings for therapeutic interventions to improve cognitive function in individuals with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349859     DOI: 10.1016/S0074-7742(06)78004-7

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  40 in total

Review 1.  Annual Research Review: Development of the cerebral cortex: implications for neurodevelopmental disorders.

Authors:  John L R Rubenstein
Journal:  J Child Psychol Psychiatry       Date:  2010-08-24       Impact factor: 8.982

2.  Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.

Authors:  Beng-Choon Ho; Thomas H Wassink; Steven Ziebell; Nancy C Andreasen
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

Review 3.  The future of ultra-high field MRI and fMRI for study of the human brain.

Authors:  Jeff H Duyn
Journal:  Neuroimage       Date:  2011-10-28       Impact factor: 6.556

4.  Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT.

Authors:  Stefano Marenco; Antonina A Savostyanova; Jan Willem van der Veen; Matthew Geramita; Alexa Stern; Alan S Barnett; Bhaskar Kolachana; Eugenia Radulescu; Fengyu Zhang; Joseph H Callicott; Richard E Straub; Jun Shen; Daniel R Weinberger
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

5.  Neonatal nicotine exposure increases excitatory synaptic transmission and attenuates nicotine-stimulated GABA release in the adult rat hippocampus.

Authors:  Joanne C Damborsky; William H Griffith; Ursula H Winzer-Serhan
Journal:  Neuropharmacology       Date:  2014-06-17       Impact factor: 5.250

Review 6.  Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.

Authors:  Matcheri S Keshavan; Henry A Nasrallah; Rajiv Tandon
Journal:  Schizophr Res       Date:  2011-02-12       Impact factor: 4.939

Review 7.  Using human brain imaging studies as a guide toward animal models of schizophrenia.

Authors:  S S Bolkan; F Carvalho Poyraz; C Kellendonk
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

Review 8.  Clonazepam improves dopamine supersensitivity in a schizophrenia patient: a case report.

Authors:  Mina Fukai; Tetsu Hirosawa; Tetsuya Takahashi; Reizo Kaneda; Mitsuru Kikuchi; Yoshio Minabe
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-02

Review 9.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

10.  GABA predicts inhibition of frequency-specific oscillations in schizophrenia.

Authors:  Laura M Rowland; Richard A E Edden; Kimberly Kontson; He Zhu; Peter B Barker; L Elliot Hong
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2013       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.